Anthracycline-induced cardiotoxicity remains a significant clinical challenge requiring early detection through biomarkers and advanced imaging, as well as the development of cardioprotective strategies.
Answers are grounded in this paper and cite their sources.
Supports continued biomarker and imaging surveillance for anthracycline cardiotoxicity; leaves open optimal cardioprotective strategies for prospective trials.
Anthracyclines, especially doxorubicin and daunorubicin, are the drugs of first choice in the treatment of patients with hematologic malignancies, soft-tissue sarcomas, and solid tumors. Unfortunately, the use of anthracyclines is limited by their dose-dependent and cumulative cardiotoxicity. The molecular mechanism responsible for anthracycline-induced cardiotoxicity remains poorly understood, although experimental and clinical studies have shown that oxidative stress plays the main role. Hence, antioxidant agents, especially dexrazoxane, and also other drug classes (statins, β-blockers) proved to have a beneficial effect in protecting against anthracycline-induced cardiotoxicity. According to previous clinical trials, the major high-risk factors for anthracycline-induced cardiotoxicity are age, body weight, female gender, radiotherapy, and other diseases such as Down syndrome, familial dilated cardiomyopathy, diabetes and hypertension. Consequently, further studies are needed to elucidate the molecular pathogenesis of anthracycline-induced cardiotoxicity and also to discover new cardioprotective agents against anthracycline-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Valcovici et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: